Reported 2 months ago
Analysts predict the anti-obesity drug market, including GLP-1 medications, could be worth $100 billion, prompting major pharmaceutical companies to invest heavily in this sector. However, Pfizer is unlikely to acquire a GLP-1 drugmaker due to its current focus on paying down substantial debt from its $43 billion acquisition of Seagen. CEO Albert Bourla has indicated that while Pfizer will pursue opportunities in the weight loss market, it will not seek out acquisitions that would exacerbate its debt situation. This cautious approach, coupled with soaring valuations in the GLP-1 sector, means investors shouldn't expect immediate acquisition deals despite Pfizer's potential in the market.
Source: YAHOO